(19)
(11) EP 3 528 848 A1

(12)

(43) Date of publication:
28.08.2019 Bulletin 2019/35

(21) Application number: 17861307.1

(22) Date of filing: 19.10.2017
(51) International Patent Classification (IPC): 
A61K 47/24(2006.01)
 A61K 31/506(2006.01)
(86) International application number:
PCT/US2017/057446
(87) International publication number:
WO 2018/075801 (26.04.2018 Gazette 2018/17)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: 19.10.2016 US 201615297901

(71) Applicant: Signpath Pharma Inc.
Sandy, UT 84092 (US)

(72) Inventors:
  • HELSON, Lawrence
    Quakertown PA 18951 (US)
  • SHOPP, George, M.
    Boulder CO 80302 (US)
  • BOUCHARD, Annie
    Stoke QC J0B 3G0 (CA)
  • MAJEED, Muhammed
    East Windsor NJ 08520 (US)

(74) Representative: Sonn & Partner Patentanwälte 
Riemergasse 14
1010 Wien
1010 Wien (AT)

   


(54) PROTECTIVE EFFECT OF DMPC, DMPG, DMPC/DMPG, EGPG, LYSOPG AND LYSOPC AGAINST DRUGS THAT CAUSE CHANNELOPATHIES